Clinical Trial Update: A Phase Ib/II Clinical Study to Evaluate HLX43 in Combination With Serplulimab in Patients With Advanced/Metastatic Solid Tumors [Phase 1, Phase 2]

View source ↗

Summary

Phase Ib/II clinical study evaluating HLX43 in combination with serplulimab for advanced/metastatic solid tumors is currently recruiting. The study includes non…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer
• Solid Tumors

Drugs mentioned

• HLX43
• Serplulimab (serplulimab)

Snippet

Sponsor: Shanghai Henlius Biotech | Conditions: Solid Tumor Cancer, Non Small Cell Lung Cancer | Phase 1, Phase 2 | Status: RECRUITING